Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP290628.RAhuDgYkVntEUokCqOdtFtKlsINMzBxTWBpl1SxW0c11c130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP290628.RAhuDgYkVntEUokCqOdtFtKlsINMzBxTWBpl1SxW0c11c130_provenance.
• NP290795.RAs9ccZADXHSoH_lsc_uUccS73Pr0Z0SHmQQVNAYeiyEQ130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP290795.RAs9ccZADXHSoH_lsc_uUccS73Pr0Z0SHmQQVNAYeiyEQ130_provenance.
• NP687815.RAUAqR9MNrCgXzdezA6Jz5bfOxLc1t3B2GHe3TXuYxpVI130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687815.RAUAqR9MNrCgXzdezA6Jz5bfOxLc1t3B2GHe3TXuYxpVI130_provenance.
• NP577136.RAmZyryRUuUcnnvpfVx9FpLUZ56-59X6HiWBwY-AuYAOg130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP577136.RAmZyryRUuUcnnvpfVx9FpLUZ56-59X6HiWBwY-AuYAOg130_provenance.
• NP290817.RA2itYoFt4SFT9OlynIPOhBthPv38xW1YO4uPFD-3ko3I130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP290817.RA2itYoFt4SFT9OlynIPOhBthPv38xW1YO4uPFD-3ko3I130_provenance.
• NP293473.RAwZZxurH5ltnLTZ1wYWhULXcRTVolqrttrAjqivbLwSQ130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP293473.RAwZZxurH5ltnLTZ1wYWhULXcRTVolqrttrAjqivbLwSQ130_provenance.
• NP687803.RA2jBWKrsY2uBVxaRjO2VAp418Y2uJra8Rh5Ik5Lgkbzc130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687803.RA2jBWKrsY2uBVxaRjO2VAp418Y2uJra8Rh5Ik5Lgkbzc130_provenance.
• NP687806.RA-dpzsvvFHCKEnKGaa7F0c3slV328NE3z9S7JkJtF4dw130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687806.RA-dpzsvvFHCKEnKGaa7F0c3slV328NE3z9S7JkJtF4dw130_provenance.
• NP687809.RA_GAC4pJmg78upK4-tuT8KBW2ExZUtqt4xqO7vVhEuFA130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687809.RA_GAC4pJmg78upK4-tuT8KBW2ExZUtqt4xqO7vVhEuFA130_provenance.
• NP687814.RA4oJrxlbZO718IdwXnJi4JVqmE4tv4QwdZpZYsx1iPHg130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687814.RA4oJrxlbZO718IdwXnJi4JVqmE4tv4QwdZpZYsx1iPHg130_provenance.
• NP687816.RA4dP4ntpXEJNHm5tahnxFfely5Zxufn6FfVfRRVfY_N0130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687816.RA4dP4ntpXEJNHm5tahnxFfely5Zxufn6FfVfRRVfY_N0130_provenance.
• NP687817.RA-2Zomx0HLQBpIqn4vDifWH4i36FB8oUOzeMBpE7pWLM130_assertion description "[A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687817.RA-2Zomx0HLQBpIqn4vDifWH4i36FB8oUOzeMBpE7pWLM130_provenance.